Shuo Wang
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Intensive Care Unit Cognitive Disorders
Papers in
- Immunology 35
- Immune Cell Function and Interaction 19
- Immunotherapy and Immune Responses 9
-
- Cancer-related molecular mechanisms research 9
- Co-authors
- Buqing YePengyan XiaGuanling HuangZusen FanYing DuJing LiuPingping ZhuXiaohong Chen
- Journals
- Frontiers in Oncology (7 papers)BMC Cancer (4 papers)Nature Communications (3 papers)Journal of Cancer (3 papers)Frontiers in Immunology (2 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Shuo Wang
123 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 132
- Cancer Research 495
- Critical Care and Intensive Care Medicine 154
- Immunology 531
- Oncology 569
- Molecular Biology 858
Countries citing papers authored by Shuo Wang
This map shows the geographic impact of Shuo Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuo Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuo Wang more than expected).
Fields of papers citing papers by Shuo Wang
This network shows the impact of papers produced by Shuo Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuo Wang. The network helps show where Shuo Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shuo Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 1 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 10 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 5 | |
| 11 | 2023 | 3 | |
| 12 | 2022 | 3 | |
| 13 | 2022 | 3 | |
| 14 | 2021 | 5 | |
| 15 | 2019 | 8 | |
| 16 | 2019 | 7 | |
| 17 | 2018 | 52 | |
| 18 | 2017 | 46 | |
| 19 | 2017 | 45 | |
| 20 | 2016 | 17 |
About Shuo Wang
Shuo Wang is a scholar working on Immunology, Cancer Research, Oncology, Critical Care and Intensive Care Medicine and Hepatology, having authored 139 papers that have together received 2.4k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (19 papers), Cancer Immunotherapy and Biomarkers (15 papers), RNA modifications and cancer (13 papers), Bladder and Urothelial Cancer Treatments (11 papers), CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (9 papers), Cancer-related molecular mechanisms research (9 papers) and Glioma Diagnosis and Treatment (6 papers). The work is most often cited by research in Cancer Research (495 citations), Critical Care and Intensive Care Medicine (154 citations), Immunology (531 citations), Oncology (569 citations) and Molecular Biology (858 citations). Shuo Wang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Buqing Ye, Pengyan Xia, Guanling Huang, Zusen Fan, Ying Du, Jing Liu, Pingping Zhu, Xiaohong Chen, Xiaoying Jiang and Junmin Chen. Their work appears in journals such as Frontiers in Oncology, BMC Cancer, Nature Communications, Journal of Cancer and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.